NO331682B1 - Medisinsk anvendelse av histon-deacetylase inhibitor. - Google Patents
Medisinsk anvendelse av histon-deacetylase inhibitor. Download PDFInfo
- Publication number
- NO331682B1 NO331682B1 NO20040731A NO20040731A NO331682B1 NO 331682 B1 NO331682 B1 NO 331682B1 NO 20040731 A NO20040731 A NO 20040731A NO 20040731 A NO20040731 A NO 20040731A NO 331682 B1 NO331682 B1 NO 331682B1
- Authority
- NO
- Norway
- Prior art keywords
- tumor
- expression
- gene
- histone deacetylase
- cell
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001250846 | 2001-08-21 | ||
| PCT/JP2002/008355 WO2003015810A1 (en) | 2001-08-21 | 2002-08-20 | Medicinal use of histone deacetylase inhibitor and method of evaluating antitumor effect thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20040731L NO20040731L (no) | 2004-04-20 |
| NO331682B1 true NO331682B1 (no) | 2012-02-20 |
Family
ID=19079582
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20040731A NO331682B1 (no) | 2001-08-21 | 2004-02-20 | Medisinsk anvendelse av histon-deacetylase inhibitor. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8470783B2 (de) |
| EP (1) | EP1426054B1 (de) |
| JP (1) | JP4238728B2 (de) |
| AT (1) | ATE526029T1 (de) |
| CA (1) | CA2457043A1 (de) |
| DK (1) | DK1426054T3 (de) |
| ES (1) | ES2371630T3 (de) |
| HU (1) | HU229521B1 (de) |
| MX (1) | MXPA04001612A (de) |
| NO (1) | NO331682B1 (de) |
| PL (1) | PL210794B1 (de) |
| PT (1) | PT1426054E (de) |
| RU (1) | RU2298414C2 (de) |
| WO (1) | WO2003015810A1 (de) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8673888B2 (en) * | 2002-04-05 | 2014-03-18 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Depsipeptide for therapy of kidney cancer |
| US7154002B1 (en) | 2002-10-08 | 2006-12-26 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| EP1595952A4 (de) * | 2003-02-19 | 2008-05-21 | Astellas Pharma Inc | Verfahren zur abschätzung der antitumorwirkung des histondeacetylase-inhibitors |
| US7381825B2 (en) | 2003-03-17 | 2008-06-03 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| SI2238982T1 (sl) * | 2003-06-27 | 2013-01-31 | Astellas Pharma Inc. | Terapevtsko sredstvo za mehkotkivni sarkom |
| ES2425083T3 (es) * | 2003-09-25 | 2013-10-11 | Astellas Pharma Inc. | Agente antitumoral que comprende FK228 como inhibidor de histona desacetilasa y doxorrubicina como inhibidor de topoisomerasa II |
| WO2005058298A2 (en) * | 2003-12-10 | 2005-06-30 | Wisconsin Alumni Research Foundation | Fk228 analogs and their use as hdac-inhibitors |
| WO2005059167A1 (en) * | 2003-12-18 | 2005-06-30 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Method for identifying histone deacetylase inhibitors |
| US20050187148A1 (en) * | 2004-02-25 | 2005-08-25 | Yoshinori Naoe | Antitumor agent |
| US7951780B2 (en) | 2004-02-25 | 2011-05-31 | Astellas Pharma Inc. | Antitumor agent |
| KR101167601B1 (ko) * | 2004-02-25 | 2012-07-27 | 아스텔라스세이야쿠 가부시키가이샤 | 항종양제 |
| JP2006000113A (ja) * | 2004-05-20 | 2006-01-05 | Masatomo Sakurai | 漢方医療の診断に用いる遺伝子およびその利用方法 |
| EP1824831A2 (de) | 2004-12-16 | 2007-08-29 | Takeda San Diego, Inc. | Histondeacetylase-inhibitoren |
| JP5156392B2 (ja) | 2005-02-03 | 2013-03-06 | トポターゲット ユーケー リミテッド | Ｈｄａｃ阻害剤を用いる併用療法 |
| WO2006094068A2 (en) | 2005-03-01 | 2006-09-08 | The Regents Of The University Of Michigan | Hdac inhibitors that promote brm expression and brm related diagnostics |
| EP1896436A2 (de) | 2005-05-11 | 2008-03-12 | Takeda San Diego, Inc. | Inhibitoren der histondeacetylase |
| ATE542527T1 (de) | 2005-05-13 | 2012-02-15 | Topotarget Uk Ltd | Pharmazeutische formulierungen von hdac-hemmern |
| EA200800321A1 (ru) | 2005-07-14 | 2008-06-30 | Такеда Сан Диего, Инк. | Ингибиторы гистондеацетилазы |
| AU2006283677A1 (en) * | 2005-08-19 | 2007-03-01 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Topical formulations of histone deacetylase inhibitors and methods of using the same |
| WO2007054719A2 (en) | 2005-11-10 | 2007-05-18 | Topotarget Uk Limited | Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer alone or in combination with chemotherapeutic agent |
| US20070129290A1 (en) * | 2005-11-18 | 2007-06-07 | Or Yat S | Metabolite derivatives of the HDAC inhibitor FK228 |
| EP2012801A4 (de) * | 2006-04-24 | 2009-08-05 | Gloucester Pharmaceuticals Inc | Gemcitabin-kombinationstherapie |
| US8957027B2 (en) | 2006-06-08 | 2015-02-17 | Celgene Corporation | Deacetylase inhibitor therapy |
| US9408816B2 (en) | 2006-12-26 | 2016-08-09 | Pharmacyclics Llc | Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy |
| CN101687010A (zh) * | 2006-12-29 | 2010-03-31 | 格洛斯特制药公司 | 制备Romidepsin |
| AU2007342028B2 (en) * | 2006-12-29 | 2013-06-13 | Celgene Corporation | Purifiction of romidepsin |
| AU2008210421B2 (en) | 2007-01-30 | 2014-03-13 | Pharmacyclics Llc | Methods for determining cancer resistance to histone deacetylase inhibitors |
| US8642809B2 (en) | 2007-09-25 | 2014-02-04 | Topotarget Uk Ltd. | Methods of synthesis of certain hydroxamic acid compounds |
| NZ605526A (en) | 2010-07-12 | 2015-04-24 | Celgene Corp | Romidepsin solid forms and uses thereof |
| US8859502B2 (en) | 2010-09-13 | 2014-10-14 | Celgene Corporation | Therapy for MLL-rearranged leukemia |
| JP6330118B2 (ja) | 2011-09-13 | 2018-05-30 | ファーマサイクリックス エルエルシー | ベンダムスチンと組み合わせたヒストンデアセチラーゼ阻害剤の製剤とその使用 |
| AU2013202506B2 (en) | 2012-09-07 | 2015-06-18 | Celgene Corporation | Resistance biomarkers for hdac inhibitors |
| AU2013202507B9 (en) | 2012-11-14 | 2015-08-13 | Celgene Corporation | Inhibition of drug resistant cancer cells |
| NZ630311A (en) | 2013-12-27 | 2016-03-31 | Celgene Corp | Romidepsin formulations and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8817743D0 (en) | 1988-07-26 | 1988-09-01 | Fujisawa Pharmaceutical Co | Fr901228 substance & preparation thereof |
| US6030961A (en) | 1997-03-11 | 2000-02-29 | Bar-Ilan Research & Development Co., Ltd. | Oxyalkylene phosphate compounds and uses thereof |
| WO1999011659A1 (en) | 1997-09-02 | 1999-03-11 | Japan Energy Corporation | Novel cyclic tetrapeptide derivatives and medicinal use thereof |
| CA2308565A1 (en) * | 1997-11-05 | 1999-05-14 | Baylor College Of Medicine | Sequences for targeting metastatic cells |
| JPH11335375A (ja) | 1998-05-20 | 1999-12-07 | Mitsui Chem Inc | ヒストン脱アセチル化酵素阻害作用を有するベンズアミド誘導体 |
| NZ517613A (en) | 1999-09-08 | 2004-01-30 | Sloan Kettering Inst Cancer | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof |
| CN1414971A (zh) | 1999-12-08 | 2003-04-30 | 埃克斯西特治疗公司 | 用作免疫抑制剂的缩肽及其同类物 |
| CA2317003A1 (en) * | 2000-02-28 | 2001-08-28 | Hidenori Nakajima | Gene expression potentiator |
| JP2001348340A (ja) * | 2000-06-07 | 2001-12-18 | Yamanouchi Pharmaceut Co Ltd | ヒストン脱アセチル化酵素阻害剤 |
| ATE425177T1 (de) | 2000-07-17 | 2009-03-15 | Astellas Pharma Inc | Reduziertes fk228 und seine verwendung |
| US8673888B2 (en) | 2002-04-05 | 2014-03-18 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Depsipeptide for therapy of kidney cancer |
| SI2238982T1 (sl) | 2003-06-27 | 2013-01-31 | Astellas Pharma Inc. | Terapevtsko sredstvo za mehkotkivni sarkom |
| ES2425083T3 (es) | 2003-09-25 | 2013-10-11 | Astellas Pharma Inc. | Agente antitumoral que comprende FK228 como inhibidor de histona desacetilasa y doxorrubicina como inhibidor de topoisomerasa II |
| US7951780B2 (en) | 2004-02-25 | 2011-05-31 | Astellas Pharma Inc. | Antitumor agent |
-
2002
- 2002-08-20 JP JP2003520768A patent/JP4238728B2/ja not_active Expired - Lifetime
- 2002-08-20 ES ES02760663T patent/ES2371630T3/es not_active Expired - Lifetime
- 2002-08-20 PL PL368708A patent/PL210794B1/pl unknown
- 2002-08-20 CA CA002457043A patent/CA2457043A1/en not_active Abandoned
- 2002-08-20 AT AT02760663T patent/ATE526029T1/de active
- 2002-08-20 US US10/486,833 patent/US8470783B2/en not_active Expired - Lifetime
- 2002-08-20 WO PCT/JP2002/008355 patent/WO2003015810A1/ja not_active Ceased
- 2002-08-20 DK DK02760663.1T patent/DK1426054T3/da active
- 2002-08-20 EP EP02760663A patent/EP1426054B1/de not_active Expired - Lifetime
- 2002-08-20 MX MXPA04001612A patent/MXPA04001612A/es active IP Right Grant
- 2002-08-20 RU RU2004108137/15A patent/RU2298414C2/ru not_active IP Right Cessation
- 2002-08-20 PT PT02760663T patent/PT1426054E/pt unknown
- 2002-08-20 HU HU0400668A patent/HU229521B1/hu not_active IP Right Cessation
-
2004
- 2004-02-20 NO NO20040731A patent/NO331682B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ATE526029T1 (de) | 2011-10-15 |
| WO2003015810A1 (en) | 2003-02-27 |
| JPWO2003015810A1 (ja) | 2004-12-02 |
| HU229521B1 (hu) | 2014-01-28 |
| EP1426054B1 (de) | 2011-09-28 |
| EP1426054A4 (de) | 2006-09-13 |
| HUP0400668A2 (hu) | 2005-01-28 |
| CA2457043A1 (en) | 2003-02-27 |
| ES2371630T3 (es) | 2012-01-05 |
| HUP0400668A3 (en) | 2012-09-28 |
| RU2298414C2 (ru) | 2007-05-10 |
| NO20040731L (no) | 2004-04-20 |
| PL210794B1 (pl) | 2012-03-30 |
| PT1426054E (pt) | 2011-12-06 |
| PL368708A1 (en) | 2005-04-04 |
| DK1426054T3 (da) | 2011-12-12 |
| US8470783B2 (en) | 2013-06-25 |
| RU2004108137A (ru) | 2005-05-10 |
| JP4238728B2 (ja) | 2009-03-18 |
| EP1426054A1 (de) | 2004-06-09 |
| MXPA04001612A (es) | 2004-07-08 |
| US20050191713A1 (en) | 2005-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO331682B1 (no) | Medisinsk anvendelse av histon-deacetylase inhibitor. | |
| WO2004074478A1 (ja) | ヒストンデアセチラーゼ阻害剤の抗腫瘍効果の予測方法 | |
| JP2019131546A (ja) | がん患者におけるがんの治療方法及び薬物応答性の予測方法 | |
| US20240108686A1 (en) | DPEP-1 Binding Compositions and Methods of Use | |
| JP6900320B2 (ja) | がんにおけるマイクロピノサイトーシス | |
| MX2011004344A (es) | Terapia contra el cancer. | |
| Nakamura et al. | Osteopontin-integrin αvβ3 axis is crucial for 5-fluorouracil resistance in oral squamous cell carcinoma | |
| Levine et al. | Androgen receptor antagonism by divalent ethisterone conjugates in castrate-resistant prostate cancer cells | |
| EP4335920A2 (de) | Verwendung von rhoa in der krebsdiagnose und beim screening von inhibitoren | |
| US11091517B2 (en) | Peptide derivative and pharmaceutical composition containing same | |
| Johnson | New targets for lymphoma treatment | |
| CN111139299A (zh) | Josd2蛋白在制备治疗恶性肿瘤药物中的应用 | |
| JP6659250B2 (ja) | 癌の検査方法、癌細胞増殖阻害剤、抗癌剤及び抗癌剤のスクリーニング方法 | |
| Gu et al. | A highly potent and selective farnesyltransferase inhibitor ABT-100 in preclinical studies | |
| CN101181627A (zh) | 一种人亲和素蛋白在制备抗肝癌药物中的应用 | |
| CN118852344A (zh) | 一种用于预防和/或治疗食道癌的肽及其用途 | |
| Scheiterle et al. | 353. PIK3CA mutation in gastric cancer and the role of different codon mutations in the new molecular division of that neoplasm | |
| TW201206427A (en) | Method for prediction of therapeutic effect of chemotherapy on breast cancer patient | |
| CN113122627A (zh) | Igfl4基因作为标志物在胃癌、结直肠癌、子宫内膜癌及卵巢癌中诊断及治疗的应用 | |
| EP2578227A2 (de) | Krebstherapieverfahren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CREP | Change of representative |
Representative=s name: PLOUGMANN 6 VINGTOFT POSTBOKS 1003 SENTRUM OSLO, 0 |
|
| MM1K | Lapsed by not paying the annual fees |